Q-omics provides the consensus-scored IPO5 profile across patient tissues and cancer cell-line models. IPO5 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, IPO5 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, IPO5 protein abundance shows 34,639 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, COAD, and LSCC as cancer lineages where IPO5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IPO5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IPO5 survival associations across molecular data types. IPO5 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IPO5 RNA expression–survival associations across cancer types. High IPO5 expression shows unfavorable associations in ACC, MESO and LIHC, but favorable associations in KIRC, UCS and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for IPO5 RNA expression.
This table summarizes IPO5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 12. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for IPO5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IPO5 shows lower tumor expression in BRCA and higher tumor expression in COAD, HNSC, READ, LIHC and CHOL. The COAD box plot shows higher IPO5 RNA expression in tumor versus normal tissue (log2 FC = +1.477, t-test p < 0.001).
This table shows molecular features associated with IPO5 in patient tissues and cancer cell lines. In patient samples, IPO5 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, IPO5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and UPPER_AERODIGESTIVE_TRACT.
